Bayer– follicular lymphoma-Pharma.jpg” />

German drug manufacturer Bayer has received priority review designation for the new drug application (NDA) for copanlisib from the US Food and Drug Administration (FDA).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The experimental drug is indicated to treat patients affected with relapsed or refractory follicular lymphoma (FL) and have received at least two prior therapies.

Bayer Pharmaceuticals America region head Carsten Brunn said: “With this milestone, we are one step closer to making copanlisib available in the US to the community of doctors and patients facing a very difficult-to-treat disease.

“We look forward to continuing to work with the FDA throughout the review process.”

See Also:

Copanlisibis is a pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against PI3K-α and PI3K-δ.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The regulatory submission for copanlisib is based on Phase II, open-label, single arm CHRONOS-1 study data that assessed patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL).

The study included 142 patients, 141 of which had iNHL.

"With this milestone, we are one step closer to making copanlisib available in the US to the community of doctors and patients facing a very difficult-to-treat disease."

CHRONOS-1 was designed to evaluate the efficacy and safety of copanlisib in the patients.

The primary endpoint of CHRONOS-1 is to assess the objective tumour response rate, while the secondary endpoints include the duration of response, overall survival, progression-free survival, quality of life and safety.

The collected data from this CHRONOS-1 trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held next month.

Non-Hodgkin's lymphoma is regarded as the seventh most common cancer in the US and estimated to affect nearly 73,000 more people this year.

Image: Micrograph showing a small B-cell lymphoma compatible with follicular lymphoma. Photo: courtesy of Nephron.